| GTO ID | GTC3614 |
| Trial ID | NCT06077760 |
| Disease | Lung Non-Small Cell Carcinoma |
| Therapy | mRNA vaccine |
| Treatment | V940|mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer |
| Year | 2023 |
| Country | United States|Australia|Costa Rica|New Zealand|China |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V940-002|2023-504923-20|U1111-1290-3969 |
| Vector information | |||
|
|||
| Cohort1: V940 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||